BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9145840)

  • 1. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
    Khan AA; Slifer T; Araujo FG; Polzer RJ; Remington JS
    Antimicrob Agents Chemother; 1997 May; 41(5):893-7. PubMed ID: 9145840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
    Araujo FG; Suzuki Y; Remington JS
    Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
    Araujo FG; Lin T; Remington JS
    J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
    Romand S; Pudney M; Derouin F
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifabutin is active in murine models of toxoplasmosis.
    Araujo FG; Slifer T; Remington JS
    Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
    Araujo FG; Khan AA; Bryskier A; Remington JS
    J Antimicrob Chemother; 1998 Nov; 42(5):665-7. PubMed ID: 9848454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trovafloxacin is active against Toxoplasma gondii.
    Khan AA; Slifer T; Araujo FG; Remington JS
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1855-9. PubMed ID: 8843293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
    Moshkani SK; Dalimi A
    Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
    Romand S; Della Bruna C; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
    Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
    Djurković-Djaković O; Nikolić A; Bobić B; Klun I
    Chemotherapy; 2004 Jun; 50(3):155-6. PubMed ID: 15272229
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
    Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
    Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
    Martins-Duarte ÉS; de Souza W; Vommaro RC
    Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
    Sordet F; Aumjaud Y; Fessi H; Derouin F
    Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
    Araujo FG; Hunter CA; Remington JS
    Antimicrob Agents Chemother; 1997 Jan; 41(1):188-90. PubMed ID: 8980778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
    Martinez A; Allegra CJ; Kovacs JA
    Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
    Araujo FG; Slifer T
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2696-701. PubMed ID: 8593005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
    Alves CF; Vitor RW
    Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
    Mahmoud MS
    J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.